Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 siRNA delivery not Toll-free.

Literature DB >> 19816445

siRNA delivery not Toll-free.

Michael P Gantier, Bryan R G Williams.

Abstract

Mesh：

Substances：

Year: 2009 PMID： 19816445 DOI： 10.1038/nbt1009-911

Source DB: PubMed Journal: Nat Biotechnol ISSN： 1087-0156 Impact factor: 54.908

× No keyword cloud information.

11 in total

1. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug.

Authors: Jennifer A MacDiarmid; Nancy B Amaro-Mugridge; Jocelyn Madrid-Weiss; Ilya Sedliarou; Stefanie Wetzel; Kartini Kochar; Vatsala N Brahmbhatt; Leo Phillips; Scott T Pattison; Carlotta Petti; Bruce Stillman; Robert M Graham; Himanshu Brahmbhatt
Journal: Nat Biotechnol Date: 2009-06-28 Impact factor: 54.908

Review 2. Activation of the mammalian immune system by siRNAs.

Authors: Joao T Marques; Bryan R G Williams
Journal: Nat Biotechnol Date: 2005-11 Impact factor: 54.908

3. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors: James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal: Nat Biotechnol Date: 2006-06-25 Impact factor: 54.908

4. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.

Authors: Marcin Kortylewski; Maciej Kujawski; Tianhong Wang; Sheng Wei; Shumin Zhang; Shari Pilon-Thomas; Guilian Niu; Heidi Kay; James Mulé; William G Kerr; Richard Jove; Drew Pardoll; Hua Yu
Journal: Nat Med Date: 2005-11-20 Impact factor: 53.440

5. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics.

Authors: Jennifer A MacDiarmid; Nancy B Mugridge; Jocelyn C Weiss; Leo Phillips; Adam L Burn; Richard P Paulin; Joel E Haasdyk; Kristie-Ann Dickson; Vatsala N Brahmbhatt; Scott T Pattison; Alexander C James; Ghalib Al Bakri; Rodney C Straw; Bruce Stillman; Robert M Graham; Himanshu Brahmbhatt
Journal: Cancer Cell Date: 2007-05 Impact factor: 31.743

6. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation.

Authors: Myriam Aouadi; Gregory J Tesz; Sarah M Nicoloro; Mengxi Wang; My Chouinard; Ernesto Soto; Gary R Ostroff; Michael P Czech
Journal: Nature Date: 2009-04-30 Impact factor: 49.962

7. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target.

Authors: Dan Peer; Eun Jeong Park; Yoshiyuki Morishita; Christopher V Carman; Motomu Shimaoka
Journal: Science Date: 2008-02-01 Impact factor: 47.728

8. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.

Authors: Mark E Kleinman; Kiyoshi Yamada; Atsunobu Takeda; Vasu Chandrasekaran; Miho Nozaki; Judit Z Baffi; Romulo J C Albuquerque; Satoshi Yamasaki; Masahiro Itaya; Yuzhen Pan; Binoy Appukuttan; Daniel Gibbs; Zhenglin Yang; Katalin Karikó; Balamurali K Ambati; Traci A Wilgus; Luisa A DiPietro; Eiji Sakurai; Kang Zhang; Justine R Smith; Ethan W Taylor; Jayakrishna Ambati
Journal: Nature Date: 2008-03-26 Impact factor: 49.962

9. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone.

Authors: Yasushi Sato; Kazuyuki Murase; Junji Kato; Masayoshi Kobune; Tsutomu Sato; Yutaka Kawano; Rishu Takimoto; Kouichi Takada; Koji Miyanishi; Takuya Matsunaga; Tetsuji Takayama; Yoshiro Niitsu
Journal: Nat Biotechnol Date: 2008-03-30 Impact factor: 54.908

10. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

Authors: Marcin Kortylewski; Piotr Swiderski; Andreas Herrmann; Lin Wang; Claudia Kowolik; Maciej Kujawski; Heehyoung Lee; Anna Scuto; Yong Liu; Chunmei Yang; Jiehui Deng; Harris S Soifer; Andrew Raubitschek; Stephen Forman; John J Rossi; Drew M Pardoll; Richard Jove; Hua Yu
Journal: Nat Biotechnol Date: 2009-09-13 Impact factor: 54.908

5 in total

siRNA delivery not Toll-free.

1. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug.

Review 2. Activation of the mammalian immune system by siRNAs.

3. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

4. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.

5. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics.

6. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation.

7. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target.

8. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.

9. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone.

10. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.

1. RNAimmuno: a database of the nonspecific immunological effects of RNA interference and microRNA reagents.

2. Minor-groove-modulating adenosine replacements control protein binding and RNAi activity in siRNAs.

3. Rational design of immunostimulatory siRNAs.

4. Antitumor and Antimetastatic Effect of Small Immunostimulatory RNA against B16 Melanoma in Mice.

5. Molecular Mechanism of the Antiproliferative Activity of Short Immunostimulating dsRNA.